Expansion of Frontage Laboratories Continues with Launch of New State-of-the-Art CRDMO Facility in Exton, PA

Rhea-AI Summary

Frontage Laboratories (FTHCY) has unveiled a new 46,300-square-foot GMP CRDMO facility in Exton, Pennsylvania, marking a significant expansion of its pharmaceutical and biotech services. The state-of-the-art facility features nine GMP suites, including two high-potent suites, two aseptic suites, and five non-sterile suites, supporting diverse manufacturing capabilities for various pharmaceutical formulations. The facility also includes two formulation development labs and three analytical labs, offering comprehensive services from drug development to clinical trial support. This expansion complements Frontage's existing services in drug substance synthesis, DMPK, safety & toxicology studies, bioanalysis, and clinical trials, positioning the company as a one-stop solution provider for pharmaceutical and biotech clients.

Positive

• New 46,300-square-foot GMP facility expands manufacturing capabilities and service offerings
• Nine specialized GMP suites enable diverse pharmaceutical production capabilities
• Comprehensive one-stop-shop solution strengthens market position in CDMO space
• Strategic location enhancement improves client proximity and response efficiency

Negative

• None.

EXTON, Pa., June 2, 2025 /PRNewswire/ -- Frontage Laboratories, Inc. officially unveiled its newest Contract Research, Development and Manufacturing Organization (CRDMO) facility during a grand open house event held on May 22, 2025, at its campus in Exton, Pennsylvania.

The event marked the official launch of 46,300-square-foot Good Manufacturing Practice (GMP) facility located at 240 Sierra Drive. This expansion enhances Frontage's CRDMO footprint and reinforces its commitment to accelerating pharmaceutical and biotech innovation. This facility includes nine (9) GMP suites: two (2) high-potent suites, two (2) aseptic suites, and five (5) non-sterile suites, supporting manufacturing for injectables, tablets, capsules, creams, gels, ointments, ophthalmic and nasal preparations. This building also houses two (2) formulation development labs, and three (3) analytical labs including a micro lab. It provides a comprehensive, one-stop-shop solution for pharmaceutical and biotech clients covering all aspects of clinical supplies, including formulation development, manufacturing, analytical testing, packaging, labelling, distribution, and storage.

This expansion complements Frontage's existing service offerings, which include drug substance synthesis, DMPK, safety & toxicology studies, bioanalysis, and clinical trial support.

"We are grateful to all who joined us to share in our joyous occasion. The grand opening of this new CRDMO marks a significant milestone for us in the CDMO and clinical trial material supply space," said Dr. Song Li, Founder and Executive Chairman of Frontage. Dr. Wentao Zhang, Co-CEO of Frontage Laboratories, added, "For years, Frontage has been expanding by opening new sites and acquiring existing ones. The launch of our new state-of-the-art CDMO facility significantly enhances our manufacturing capabilities, positioning us closer to our clients and enabling us to respond more efficiently to their evolving development and supply needs."

About Frontage

Frontage Laboratories, Inc., a wholly owned subsidiary of Frontage Holdings Corporation (HKEX: 1521.HK), is a US based global CRDMO offering end-to-end integrated product development services from drug discovery through late-phase clinical trials and manufacturing. With over 25 years of experience, Frontage supports pharmaceutical and biotech companies with services including drug discovery, API synthesis, DMPK, safety and toxicology, formulation development, GMP manufacturing, analytical services, clinical trials, bioanalytical services and central lab operations.

Frontage operates 26 sites worldwide and has played a pivotal role in helping clients secure regulatory approvals across the US, Canada, Europe, and Asia.

For more information, visit www.frontagelab.com or email info@frontagelab.com.

Media Contact:
Xiaoyun Niu
xniu@frontagelab.com
(610) 232-0100

View original content to download multimedia:https://www.prnewswire.com/news-releases/expansion-of-frontage-laboratories-continues-with-launch-of-new-state-of-the-art-crdmo-facility-in-exton-pa-302470950.html

SOURCE Frontage Laboratories, Inc.

FAQ

What is the size and location of Frontage Laboratories' new CRDMO facility?

The new CRDMO facility is 46,300 square feet and is located at 240 Sierra Drive in Exton, Pennsylvania.

What manufacturing capabilities does FTHCY's new facility offer?

The facility features 9 GMP suites including 2 high-potent suites, 2 aseptic suites, and 5 non-sterile suites for manufacturing injectables, tablets, capsules, creams, gels, ointments, ophthalmic and nasal preparations.

What additional services does Frontage Laboratories' new facility provide?

The facility includes 2 formulation development labs, 3 analytical labs including a micro lab, and provides services for formulation development, manufacturing, analytical testing, packaging, labelling, distribution, and storage.

When did Frontage Laboratories (FTHCY) open its new Exton facility?

Frontage Laboratories officially unveiled the new facility during a grand open house event held on May 22, 2025.

How does the new facility complement Frontage's existing services?

The facility complements Frontage's existing services in drug substance synthesis, DMPK, safety & toxicology studies, bioanalysis, and clinical trial support, creating a comprehensive one-stop-shop solution.